Woodline Partners LP Has $43.73 Million Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Woodline Partners LP increased its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 35.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 317,642 shares of the biotechnology company's stock after purchasing an additional 82,624 shares during the quarter. Woodline Partners LP owned approximately 0.52% of Ascendis Pharma A/S worth $43,730,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Virtus ETF Advisers LLC raised its position in shares of Ascendis Pharma A/S by 3.9% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,676 shares of the biotechnology company's stock worth $368,000 after acquiring an additional 100 shares in the last quarter. Legato Capital Management LLC boosted its position in shares of Ascendis Pharma A/S by 7.5% during the 4th quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company's stock valued at $264,000 after purchasing an additional 134 shares in the last quarter. Jones Financial Companies Lllp grew its stake in Ascendis Pharma A/S by 394.0% during the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after purchasing an additional 197 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in Ascendis Pharma A/S in the fourth quarter worth approximately $28,000. Finally, Blue Trust Inc. lifted its stake in Ascendis Pharma A/S by 415.2% in the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after buying an additional 328 shares during the period.

Analyst Ratings Changes

Several analysts have recently commented on ASND shares. JPMorgan Chase & Co. raised their price objective on shares of Ascendis Pharma A/S from $200.00 to $245.00 and gave the stock an "overweight" rating in a research report on Friday, May 2nd. The Goldman Sachs Group increased their target price on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Evercore ISI raised their price target on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an "outperform" rating in a report on Friday, May 2nd. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $200.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, May 12th. Finally, Royal Bank of Canada upped their price objective on shares of Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. One analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $216.07.

Ascendis Pharma A/S Stock Performance

Shares of ASND opened at $160.33 on Tuesday. The firm has a market capitalization of $9.78 billion, a P/E ratio of -22.58 and a beta of 0.41. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $183.00. The stock has a 50 day moving average price of $157.35 and a two-hundred day moving average price of $142.88.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The company had revenue of $123.97 million during the quarter, compared to analyst estimates of $98.56 million. On average, equities analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.